Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist

Por Garner, Rachel, Gopalakrishnan, Shobha, McCauley, John A., Bednar, Rodney A., Gaul, Stanley L., Mosser, Scott D., Kiss, Laszlo, Lynch, Joseph J., Patel, Shil, Fandozzi, Christine, Lagrutta, Armando, Briscoe, Richard, Liverton, Nigel J., Paterson, Blake M., Vornov, James J., Mazhari, Reza
Publicado no Pharmacol Res Perspect (2015)

Discovery of 3-Substituted Aminocyclopentanes as Potent and Orally Bioavailable NR2B Subtype-Selective NMDA Antagonists

Por Layton, Mark E., Kelly, Michael J., Rodzinak, Kevin J., Sanderson, Philip E., Young, Steven D., Bednar, Rodney A., DiLella, Anthony G., Mcdonald, Terrence P., Wang, Hao, Mosser, Scott D., Fay, John F., Cunningham, Michael E., Reiss, Duane R., Fandozzi, Christine, Trainor, Nicole, Liang, Annie, Lis, Edward V., Seabrook, Guy R., Urban, Mark O., Yergey, James, Koblan, Kenneth S.
Publicado em 2011